Teva gains as first-quarter profit falls less than expected. » Read More
CNBC's Meg Tirrell reports on Alder Biopharmaceuticals' chronic migraine drug trial and how other pharma companies are developing new treatments and therapies, as well as the latest on Valeant CEO Mike Pearson's subpoena.
CNBC "Halftime Report" trader Jon Najarian on Tuesday bought Teva Pharmaceutical Industries for his model portfolio.
Several food items have been recalled this week, including junk food favorites like pizza and chicken nuggets.
A daily morning look at the financial stories you need to know to start the day.
U.S. stock index futures indicated a sharply lower open on Thursday.
Jim Cramer shares his opinion on caller favorite stocks, including this popular auto industry play.
Dec 9- An advisory committee to the U.S. Food and Drug Administration recommended on Wednesday that the agency approve Teva Pharmaceutical Industries Ltd's. The panel voted unanimously that the drug should not be approved for children aged 12 to 17.. The FDA is not required to follow the advice of its expert advisory panels, but typically does so.
Dec 8- Israel's Teva Pharmaceutical Industries said the U.S. Food and Drug Administration approved an injectable and infusion version of its cancer drug bendamustine. The drug, sold under the brand name Bendeka, is approved for treating cancer patients with chronic lymphocytic leukemia and indolent B-cell non-Hodgkin lymphoma. Teva, which has licensed the...
A possible deal between Ireland-based Allergan and U.S. drugmaker Pfizer raises questions about another pharmaceutical tax inversion.
Despite economic uncertainties, M&A targets in Asia totaled $770.9 billion, overtaking Europe as the second most active region, after the U.S.
Jim Cramer speaks to the CEO of Allergan on the impact of Hillary Clinton's tweet about drug pricing and her impact on the industry.
“Mad Money” host Jim Cramer on what’s behind today’s decline in media stocks.
Jim Cramer spoke to the CEO of Allergan fresh off its quarterly earnings. Did the stock deserve its beating it got?
U.S. stocks were tipped to open lower on Thursday, with focus turning to second-quarter economic growth data for clues on the timing of a rate rise.
Leon Cooperman wouldn't be buying energy stocks aggressively, but here is where he is putting his money.
U.S. stocks closed lower under pressure from an overnight plunge in the Shanghai Composite and a continued decline in commodities.
European stock closed lower on Monday, after a sharp selloff in Asian shares highlighted concerns about Chinese market volatility and slowing growth.
The Fed meets next week, but a commodities meltdown and earnings season are adding to concerns about global growth and may steal some of its thunder.
Some of the names on the move ahead of the open.
Allergan chief Brent Saunders says the sale of its generics business would allow the company to double down on its higher margin branded business.